Company ProfilePremium

Polynovo Ltd.

Company Profile Analysis

Ticker: PNV.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Polynovo Ltd. - Company showcase

Year Founded & Workforce

2004

301 Employees

Polynovo Ltd. logo

Polynovo Ltd. Employee Contacts

27 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Polynovo Ltd. Overview

PolyNovo is an Australian medical-technology company built on NovoSorb®, a proprietary family of fully synthetic, bioabsorbable polyurethane-based polymers that came out of CSIRO research. Its flagship product, NovoSorb® BTM (Biodegradable Temporising Matrix), is a bilayer synthetic dermal scaffold. Clinicians use it to rebuild a vascularised dermis after full-thickness burns, trauma, necrotising infection, oncologic resection and other complex wounds, before definitive skin grafting. A second product, NovoSorb® MTX, is a membrane-free dermal matrix that is broadening the company's reach into deeper, irregular and chronic wounds. NovoSorb® SynPath® is being positioned for the US outpatient market. In FY26 the company generated A$150.0m of total revenue and A$138.4m of commercial sales; the US contributed about 74% of sales. It was EBITDA- and NPAT-positive and free-cash-flow positive. The near-term value drivers are a planned US FDA Premarket Approval (PMA) submission for BTM in full-thickness burns before the end of CY2026, US outpatient reimbursement, MTX adoption and new manufacturing capacity in Port Melbourne.


Company's own description (AR2026, paraphrased). PolyNovo calls itself a Melbourne-headquartered medtech company transforming the management of acute and complex wounds. Its products, NovoSorb® BTM and NovoSorb® MTX, are intended to improve outcomes across a wide range of wound types. The company reports more than 127,000 patients treated in more than 50 countries. Its stated principal activity is developing medical devices from the NovoSorb® polymer. That polymer can be produced as foams, coatings, fibres, plastic structures, films and biologic carriers, and the company claims advantages over competing bioabsorbable polymers in design flexibility, bioabsorption and biocompatibility.

Independent characterisation. PolyNovo is a single-platform, single-franchise advanced wound-care company. In FY26 BTM made up about 91% of commercial sales and MTX about 9%. Its core market is US hospital inpatient burn and trauma surgery. PolyNovo sells a synthetic alternative to (a) collagen/bovine dermal templates, chiefly Integra's dermal regeneration template, (b) cadaveric allograft used as temporary cover, and (c) flap-based reconstruction in some indications. The synthetic chemistry is clinically differentiated by its reported tolerance to bacterial contamination and its lower risk of matrix loss through infection. It also carries no xenogeneic material, and as a fully synthetic product it is easier to manufacture at scale than biologics. On the company's own inventory-based definition, gross margins are in the high 80s to mid 90s per cent.

Revenue model. Almost all revenue is product sales of single-use devices sized by area and thickness, sold per unit to hospitals.

Source: FY26 results presentation (26-Aug-2026); AR2026 Directors' Report. PolyNovo has no subscription or licensing revenue. Management said in FY26 that it intends to build a business-development function to pursue partnering and licensing of NovoSorb® formulations outside its core commercial strengths.

Value chain position. PolyNovo is vertically integrated from polymer synthesis to finished sterile device. Manufacturing is concentrated in Port Melbourne. The company sells directly in Australia, Hong Kong, India, Malaysia, New Zealand, Singapore, the UK and the US, and uses distributors elsewhere: PMI (Germany), Medival (Italy), Woondz (France), Arbor Vitae International (eight Balkan markets) and a Japanese distributor for planned entry into Japan.

Customers and end-markets. The direct customers are hospitals: burn units, trauma centres, plastic and reconstructive surgery, vascular/limb salvage, orthopaedics, general surgery and surgical oncology, plus, increasingly, outpatient and wound-clinic settings. The US had 880+ hospital accounts at FY26, with 200 added during the year. Globally, 252 new hospital accounts were added in FY26. In the US, sales from indications other than large burns grew at a 52.8% three-year CAGR, against 19.1% for large burns and 30.9% for all indications (FY26 presentation). The mix is shifting from episodic, event-driven burn volumes toward more predictable complex-wound procedures.

Strategy

Stated strategy (AR2026 / FY26 investor presentation)

PillarStated components
Scale the CoreAdvance leadership in burn care in key markets; grow procedural share in complex wounds; expand access by leveraging the PMA
Leverage the PlatformBuild, partner and prioritise for growth; shape the next generation of NovoSorb® innovation; progress strategic business development
Build a Global EnterpriseAugment the manufacturing footprint; drive accountability through aligned focus; scale globally while protecting culture and values
RegionLevers
AmericasSubmit and capitalise on the PMA; launch SynPath and extend the outpatient presence; increase procedural share in existing accounts; drive MTX adoption
EMEABuild on portfolio versatility across specialties; launch MTX in the UK; accelerate new distributor markets; grow evidence and KOL engagement
APACSustain non-burn growth; accelerate MTX in Australia, Hong Kong and NZ; deepen penetration; add dedicated coverage in Malaysia

The FY26 strategy is titled "Proven Platform. Scaling for Growth." It has three pillars:

FY27 priorities (verbatim themes): (1) secure PMA approval and evidence-based expansion; (2) launch NovoSorb® SynPath® for the US outpatient market; (3) accelerate NovoSorb® MTX adoption; (4) increase innovation velocity and build business-development capability; (5) deliver greater operating leverage and profitability as the business scales.

Regional growth levers (FY26 presentation)

Strategic initiatives in the last 24 months

InitiativeTimingDetail / targets
US PMA for BTM (full-thickness burns)Submission before end of CY2026Clinical Study Report finalised on 12-month data. The submission will include 18-month follow-up. The plan was revised after updated FDA QMS guidance took effect in February 2026, with priority given to validating and documenting manufacturing and supplier processes.
US outpatient strategy and SynPath launchFY27Dedicated outpatient team covering marketing, market access, reimbursement and market development. Clinical evidence package submitted to CMS on 31 Oct 2025 to support Medicare coverage of BTM under the skin-substitute LCDs. Company asked CMS to place BTM under SynPath's HCPCS A2006 or issue a new code. An MTX HCPCS application is in preparation.
MTX global rolloutFY25–FY27Six markets live; UK and EU MDR clearance targeted in FY27; Taiwan, Brazil and Mexico in progress
Manufacturing expansionAug 2024 to FY27New Port Melbourne facility completed; validation ongoing; transition in FY27; A$1.5m machinery capex outstanding
R&D reprioritisationFY26–FY27CSO appointed; formal NPD and Portfolio Prioritisation framework; hernia and implant programs under commercial-options review; "indication-first" approach
Business-development functionFY27New team to pursue partnering and licensing of NovoSorb® formulations and adjacencies
Governance renewalMar 2025 to Apr 2026New Chair, three new directors, separate committees, board skills matrix, new GC/CoSec, policy refresh
Remuneration reformFrom FY27LTI plan introduced; enhanced disclosure
Investor communicationsFeb 2026Interactive investor hub launched; management promises "clarity and consistency" in communication
ESG / climateFY25–FY26Full value-chain GHG inventory; AASB S2 gap assessment; carbon-neutral certification (Australian operations)
Market entryFY26–FY27BTM registered in 8 new markets in FY26; Japan entry plan progressing with PMDA consultation via a distributor; Mexico registrations under way

Medium-term targets and guidance

PolyNovo has not issued formal quantitative FY27 revenue or earnings guidance in the materials reviewed. The qualitative guidance is to deliver greater operating leverage and profitability as the business scales and to accumulate cash in FY27 if current trends continue. The last numeric guidance was for 1H FY25 / FY25 (revenue growth of 20–25% and EBITDA growth of 30–35%, per the February 2025 presentation summary). Former CEO Raote had spoken of a 25% growth ambition. Management has also cited a long-term addressable-market aspiration of about A$500 million in revenue (AR2023 context); this is not a current target.

Products & Services

Commercial products (NovoSorb® wound-care franchise)

ProductDescription and key capabilitiesTarget customer / indicationsRegulatory status and launch timingPricing model
NovoSorb® BTM (Biodegradable Temporising Matrix)Bilayer synthetic dermal matrix: a biodegradable polyurethane foam scaffold with a temporary sealing membrane. It regenerates the dermis lost through extensive surgery, trauma or burns. Once the matrix is integrated, the wound is closed with a split-thickness skin graft or by secondary intention. Clinicians report strong integration even over poorly vascularised beds such as exposed bone and tendon, and reported tolerance to bacterial contamination.Burn, trauma, plastic/reconstructive, vascular/limb-salvage, orthopaedic, general and oncologic surgeons; full-thickness burns, necrotising soft-tissue infection, degloving, skin-cancer resections, chronic woundsCleared/registered in 50+ countries. US: FDA 510(k) cleared (initial clearance year not re-verified in this dossier); up to 6 mm thickness cleared June 2025. US PMA for an on-label full-thickness burns indication targeted for submission before end of CY2026. Registered in 7 new European countries in FY26 (Latvia, Lithuania, Estonia, Croatia, Slovenia, Albania, Serbia) and in Brazil.Per-unit device sales to hospitals by size and thickness; list prices not publicly disclosed
NovoSorb® MTXFully synthetic, membrane-free dermal matrix. Suits deep wounds, irregular geometries and highly exudative wounds. Can be used alone or layered with BTM.Same surgical base plus clinicians treating chronic and deep wounds outside the operating theatreFDA 510(k) 2 mm (2022); up to 6 mm (Mar 2025). TGA 2 mm (Mar 2025), 4/6 mm (May 2025). CDSCO India (Mar 2025). Health Canada (Apr 2025). Hong Kong registered in FY26. Commercial in 6 markets (Australia, US, Canada, Hong Kong, India, NZ). UK registration under way; EU MDR clearance targeted in FY27; Taiwan, Brazil and Mexico in progress. US launch Apr 2024; Australian launch 2025.Per-unit device sales; prices not publicly disclosed. A new US HCPCS code application was being prepared (Jan 2026).
NovoSorb® SynPath®NovoSorb®-based dermal matrix brand created for the US outpatient/physician-office setting. It holds an existing HCPCS code (A2006), which management calls the fastest route to outpatient reimbursement.US outpatient wound-care clinicians (for example diabetic foot and venous leg ulcers), often in accounts that already use BTM as inpatientsUS commercial launch planned for FY27Reimbursed under the CMS CY2026 flat-rate framework for 510(k) skin substitutes; product pricing not publicly disclosed
SUPRATHEL® (third-party, distribution only)Synthetic resorbable skin substitute made by PolyMedics InnovationsBurn and wound clinicians in the UK, Australia and NZExclusive distribution rights reported from May 2024 (secondary source; not re-verified in primary filings)Distribution margin; terms not publicly disclosed

Development pipeline and platform programs

ProgramDescriptionStatus (latest disclosure)
BTM life-cycle innovationNext-generation BTM aimed at shorter time-to-graft and shorter hospital length of stayActive; part of the "indication-first" R&D approach under the new CSO (AR2026)
Novel NovoSorb® formulationsPlatform innovations beyond BTM/MTXBeing prioritised under a new New Product Development and Portfolio Prioritisation framework (AR2026)
Hernia repair devices (historically "Syntrel")Bioabsorbable hernia and tissue-reinforcement devicesSignificant technical work and encouraging pre-clinical data, but management says industry dynamics have shifted and commercialisation options are under review (AR2026)
Plastics and reconstructive implantables (incl. breast reconstruction)Implantable NovoSorb® structuresUnder the same capital-allocation review as hernia (AR2026)
NovoSorb® Dermal Beta Cell ImplantScaffold hosting pancreatic islets in the skin (type 1 diabetes cell therapy), partnered with Beta Cell Technologies Pty LtdPositive first-in-human proof of concept; PolyNovo supplying BTM for clinical trials (FY25 trading update)
Drug-elution depotsNovoSorb® as a drug carrierEarly stage (third-party profiles); no recent primary disclosure

Financial Narrative

Income statement

Sources: FY22 results (26-Aug-2022: NPAT −A$1,192,532; FY22 revenue A$41.9m and sales A$37.6m per the AR2023 KPI panel); AR2023 (FY23); FY24 results (23-Aug-2024); FY25 results / Capital Brief; FY26 results presentation and AR2026. No dividend has been paid or recommended (AR2026). Market-data aggregator Stoxray shows "revenue" of A$41.4m (FY22), A$65.2m (FY23) and A$103.2m (FY24) because it excludes some other income; the company-reported totals above take precedence. FY23 non-commercial revenue is about A$6.9m and FY22 about A$4.3m (by subtraction).

Significant items reconciliation (FY26 presentation)

Margins and growth (computed on total revenue unless stated)

Revenue CAGR (computed). Total revenue grew at about 37.6% a year from FY22 (A$41.9m) to FY26 (A$150.0m). Commercial sales grew at about 38.5% a year (A$37.6m to A$138.4m). The FY24–FY26 two-year CAGR in commercial sales was about 22.6%.

Commentary.

Growth: Revenue has compounded at close to 40% a year over four years, but growth has slowed every year since FY23: sales growth went from 58.5% to 54.4% to 28.9% to 16.7% reported. Part of the FY26 slowdown is currency. Constant-currency growth was 21.3%, because the US dollar weakened against the Australian dollar over the year. The second half of FY26 (sales of about A$70.2m) was barely above the first half (A$68.2m). Management attributed 1H softness to temporary manufacturing output reductions and FX. Q1 FY26 had shown sales growth of 33.3% (A$34.7m), so 2H growth was well below 1H. On the August 2026 call management said July 2026 was a record sales month.

Gross margin: The company's margin measure (sales less change in finished goods and WIP) fell from 95.6% to 89.0%. Management attributes this to inventory movements during manufacturing optimisation. Output in 2H FY26 was 3.8 times 1H, and inventory fell from A$14.5m to A$9.8m. The underlying unit economics of a synthetic polymer device remain very attractive, but reported gross margin is now closer to 89%.

Operating leverage: Underlying EBITDA rose 50.4% on 16.7% sales growth. Underlying employee costs grew only 4.3% (excluding share-based payments), and underlying corporate and overhead costs fell 1.1% (excluding FX). The cost base of about 300 people is now absorbing growth. That is the main inflection of FY26.

Net profit: NPAT fell 44.5% to A$7.3m. FY25 was flattered by a A$5.7m tax benefit from recognising tax losses; FY26 carried a A$0.5m tax expense. FY26 also included a A$4.7m asset write-off from the R&D fire, offset by a A$6.0m insurance receipt, plus a A$2.7m unrealised FX loss.

R&D: R&D costs fell 36.9% to A$5.3m as the BARDA-funded pivotal trial completed. BARDA revenue is falling with it (A$8.6m to A$5.3m) and should approach zero.

Balance sheet: notes and sources

Sources: AR2023 KPI panel (FY22 and FY23 cash; the FY22 A$6.1m figure is taken from the KPI panel's paired label and should be treated with caution); FY24 results (A$45.9m); FY25 and FY26 presentations. FY26 borrowings were A$3.632m: an equipment finance facility of A$2.218m and an insurance premium funding facility of A$1.414m (AR2026). FY26 "Other" current assets include an insurance receivable of A$1.6m.

Cash flow

Sources: FY26 presentation (OCF, capex, FCF and debt repayment); FY25 OCF from the FY26 presentation comparative; FY24 OCF and FCF from FNArena (aggregator; secondary). FY26 capex was A$12.4m for completing the manufacturing facility and A$1.4m for rebuilding the R&D facility, which is covered by insurance. A further A$1.5m of machinery capex is payable in 1H FY27. FY26 OCF includes A$3.5m of insurance receipts. The FY26 cash bridge ran: opening A$33.5m, plus OCF A$23.1m, less capex A$13.8m, less debt repayment A$5.3m, less FX and other A$2.1m, giving closing cash of A$35.4m. Before that, the company raised about A$53m of equity in November 2022.

Commentary. FY26 was the first year of clear self-funding. Operating cash flow rose by A$20.0m on better working-capital management: receivables fell 9% and inventories fell 32% while sales grew 17%. With most of the manufacturing capex now spent, management expects cash to keep building in FY27 if trading continues as it is.

Ratios (computed unless stated)

Notes: interest expense was A$0.9m in both FY25 and FY26 (FY26 presentation).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

# Details

#SubsidiaryRole
1

PolyNovo Biomaterials Pty Limited

Australian proprietary company (technology/IP heritage)

2

NovoSkin Pty Ltd

Australian proprietary company

3

NovoWound Pty Ltd

Australian proprietary company

4

PolyNovo NZ Ltd

Trading/employment entity, New Zealand

5

PolyNovo UK Ltd

Trading/employment entity, UK

6

PolyNovo North America LLC

Trading/employment entity, US

7

PolyNovo Singapore Private Ltd

Trading/employment entity, Singapore

8

PolyNovo Ireland Ltd

Trading/employment entity, Ireland

9

PolyNovo Biomaterials India Private Ltd

Trading/employment entity, India

10

PolyNovo Hong Kong Ltd

Trading/employment entity, Hong Kong

Products

ProductFY2024FY2025FY2026

NovoSorb BTM sales (AUD Mn)

—112.0125.8

NovoSorb MTX sales (AUD Mn)

—6.712.6

Total NovoSorb commercial sales (AUD Mn)

92.0118.6138.4

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY2025FY2026

BTM YoY growth reported (%)

—12.3

BTM YoY growth constant currency (%)

—16.4

MTX YoY growth reported (%)

—89.6

MTX YoY growth constant currency (%)

—98.9

BTM share of commercial sales (%)

94.490.9

MTX share of commercial sales (%)

5.69.1

Products (Half-Yearly)

Product1H FY20231H FY20241H FY20251H FY2026

NovoSorb BTM (AUD Mn)

27.342.152.062.0

NovoSorb MTX (AUD Mn)

—0.12.16.2

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Total revenue incl. BARDA and other income (AUD Mn)

41.966.5104.8129.2150.0

NovoSorb commercial sales (AUD Mn)

37.659.692.0118.6138.4

BARDA revenue (AUD Mn)

———8.65.3

Other income (AUD Mn)

———2.06.3

Changes in inventories and WIP (COGS proxy, AUD Mn)

———5.215.2

Gross margin on company definition (%)

———95.689.0

Employee-related expenses (AUD Mn)

———74.578.8

R&D costs incl. clinical (AUD Mn)

———8.55.3

Corporate, admin and overhead (AUD Mn)

———29.934.5

EBITDA reported (AUD Mn)

——3.611.212.1

EBITDA underlying, before significant items (AUD Mn)

———8.913.4

Operating profit (AUD Mn)

———7.57.8

Income tax benefit (+) / expense (−) (AUD Mn)

———5.7-0.5

Net profit after tax (AUD Mn)

-1.2-4.95.313.27.3

Basic EPS computed (A cents)

———1.91.1

Dividends per share (A cents)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement

Item (AUD Mn)FY2025FY2026

Reported EBITDA (AUD Mn)

11.212.1

Add: write-off of assets from R&D fire (AUD Mn)

0.04.7

Less: interim insurance claim (AUD Mn)

0.0-6.0

Add: unrealised FX loss / less gain (AUD Mn)

-2.22.7

Underlying EBITDA (AUD Mn)

8.913.4

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Total revenue growth (%)

—58.857.523.316.1

Commercial sales growth (%)

—58.554.428.916.7

EBITDA margin on total revenue (%)

——3.48.78.1

Underlying EBITDA margin on commercial sales (%)

———7.59.7

Net margin (%)

-2.8-7.45.110.24.9

Gross margin on company definition (%)

———95.689.0

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Cash and cash equivalents (AUD Mn)

6.146.845.933.535.4

Trade and other receivables (AUD Mn)

———24.422.2

Inventories (AUD Mn)

———14.59.8

Other current assets (AUD Mn)

———4.76.5

Total current assets (AUD Mn)

———77.173.9

Total assets (AUD Mn)

———127.5132.1

Total liabilities (AUD Mn)

———44.141.4

Net assets / total equity (AUD Mn)

———83.490.7

Total borrowings (AUD Mn)

————3.6

Net debt, negative = net cash (AUD Mn)

————-31.8

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (AUD Mn)

——5.13.123.1

Capital expenditure (AUD Mn)

————13.8

Free cash flow, company definition (AUD Mn)

——2.2—9.4

Repayment of borrowings (AUD Mn)

————5.3

Dividends paid (AUD Mn)

00000

Share buybacks (AUD Mn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2025FY2026

ROE, NPAT / average equity (%)

—8.4

ROE, NPAT / closing equity (%)

15.88.1

ROA, NPAT / average total assets (%)

—5.6

Asset turnover, total revenue / average total assets (x)

—1.16

Debt / equity (x)

—0.04

Net debt / EBITDA (x)

—-2.6

Interest coverage, EBITDA / interest expense (x)

12.413.4

Inventory days on commercial sales (days)

44.625.8

Receivable days on commercial sales (days)

75.158.5

Revenue by Region

RegionFY2022FY2023FY2024FY2025FY2026

United States sales (AUD Mn)

31.946.168.788.4102.1

Rest of World sales (AUD Mn)

5.813.523.330.336.3

Total NovoSorb sales (AUD Mn)

37.659.692.0118.6138.4

Region Margins & Growth (%) and Revenue by Region (%)

MetricFY2023FY2024FY2025FY2026

US sales growth reported (%)

44.549.028.715.6

ROW sales growth reported (%)

132.872.630.020.0

US share of sales (%)

77.374.774.573.8

ROW share of sales (%)

22.725.325.526.2

Revenue by Region (FY2025–FY2026)

RegionFY2025FY2026

Americas sales (AUD Mn)

90.8104.1

EMEA sales (AUD Mn)

17.620.6

APAC sales (AUD Mn)

10.213.7

Region growth (%)

Region growth (%)FY2026 reported (%)FY2026 constant currency (%)

Americas

14.720.2

EMEA

17.317.6

APAC

33.637.8

Markets

MarketFY26 growth disclosedBasisSource

Turkey

79.0%

constant currency

FY26 presentation

India

52.8% (cc); 35.4% (AUD)

cc / AUD

FY26 presentation; AR2026

Hong Kong

49.9% (cc); 43.0% (AUD); 10 new hospital accounts

cc / AUD

FY26 presentation; AR2026

Ireland

38.3%

constant currency

FY26 presentation

Australia

33.9% (cc); ANZ +26.0% (AUD)

cc / AUD

FY26 presentation; AR2026

DACH (Germany, Austria, Switzerland)

15.5%

constant currency

FY26 presentation

UK

12.9%

AUD

AR2026

Taiwan

Fastest-growing APAC market (distributor-led)

qualitative

AR2026

Malaysia

First full year, ahead of plan with one representative

qualitative

AR2026

Share Price History

DatePrice (AUD)ContextSource

24 May 2023

1.43—

Kalkine

20 Oct 2023

1.12

FY24 low

Motley Fool

Jul 2024

2.59

FY24 high

Motley Fool

7 Mar 2025

about 1.28–1.34

CEO exit news

Capital Brief; People Matters

14 May 2025

1.51—

FNArena

30 Jul 2025

1.36

After FY25 trading update

Kalkine

27 Oct 2025

1.345–1.36

Chair resigns

Business News Australia; Capital Brief

24 Feb 2026

0.93

After 1H FY26 results

Motley Fool data

24 Sep 2026

0.98

Latest verified close

Fintel

Valuation Snapshot

MultipleValueBasis

Market capitalisation

about A$677m

0.98 × 690.84m

Enterprise value

about A$645m

Market cap − cash A$35.4m + borrowings A$3.6m (leases excluded)

P/E (FY26 statutory)

about 92x

NPAT A$7.3m

EV/EBITDA (FY26 reported)

about 53x

EBITDA A$12.1m

EV/EBITDA (FY26 underlying)

about 48x

Underlying EBITDA A$13.4m

EV/Sales (FY26 commercial sales)

about 4.7x

A$138.4m

EV/Revenue (FY26 total)

about 4.3x

A$150.0m

P/B

about 7.5x

Net assets A$90.7m

Broker / Aggregate Details

Broker / aggregateRatingTarget (AUD)Date

Consensus (Fintel average)

—

1.28 (from 1.75 in Jun 2026; earlier 1.38)

Sep 2026

Macquarie

Outperform (maintained)

—

Jan, Feb and Jun 2026

Canaccord Genuity

Buy (maintained)

—

Feb 2026

Bell Potter

Buy (maintained)

—

Feb and Jul 2026

Evans & Partners

Speculative Buy

2.65

Oct 2025

Wilsons

—

1.85 (cut from 3.00)

Mar 2025

Capital Markets

ItemDetail

Dividend history

None ever paid; none paid or recommended for FY26 (AR2026)

Dividend policy

No formal policy; cash reinvested in growth

Buybacks

None authorised or executed

Credit ratings (Moody's / S&P / Fitch)

Not rated

Debt maturity profile

A$3.632m total borrowings at 30 Jun 2026: equipment finance A$2.218m and insurance premium funding A$1.414m. A$5.3m of borrowings was repaid in FY26.

Capital raising history

About A$53m equity raise in Nov 2022 (most recent)

Analyst Conclusions

Management guidance

There is no quantitative FY27 guidance. The qualitative message is a focus on execution, record July 2026 sales, cash accumulation in FY27 if trends hold, and more operating leverage and profitability as the business scales. The five FY27 priorities are the PMA, the SynPath launch, MTX acceleration, innovation and business-development capability, and operating leverage.

Consensus expectations

A Simply Wall St narrative from August 2025 modelled revenue of about A$230.5m and earnings of about A$41.0m by FY28, implying about 21% annual revenue growth. Against the FY26 actual of A$150.0m, that path now looks demanding. The cut in the average price target to about A$1.28 suggests forecasts have been revised down since mid-2026.

Bull case

  1. PMA as a step change. A successful PMA would give BTM an on-label US full-thickness burns indication, backed by what management describes as the most comprehensive Level 1 RCT in US dermal substitutes. It would also place BTM in the CMS OPPS PMA payment class (APC 6000) and support conversion of remaining allograft users.

  2. Operating leverage is real. Underlying EBITDA rose 50.4% on 16.7% sales growth with flat headcount (about 301). BARDA trial costs are rolling off, and the new facility should restore gross margin toward the low-to-mid 90s per cent once fully validated. Free cash flow turned positive (A$9.4m) with most capex finished.

  3. Optionality beyond burns. US non-burn indications are growing at a 52.8% three-year CAGR, and MTX nearly doubled to A$12.6m. SynPath opens a US outpatient market that CMS has repriced to the disadvantage of high-cost biologics. Platform licensing (implantables, cell-therapy scaffolds) is unpriced at about 4.7x EV/sales.

Bear case

  1. Growth is decelerating structurally. Reported sales growth slowed from 54% to 29% to 17% over three years, and 2H FY26 sales (about A$70.2m) were nearly flat on 1H (A$68.2m). Burns volumes are lumpy, and the US sales force (106) is now large enough that productivity gains, not headcount, must drive growth.

  2. Execution risk is concentrated. About 91% of sales come from one product, from one manufacturing site that already disrupted 1H FY26 results, in one main market (74% US) exposed to FX and tariffs. The PMA timeline has already slipped once, and FDA review of a novel synthetic Class III submission could take longer than expected.

  3. The reimbursement environment is unsettled. CMS has said it may bundle skin substitutes into procedure payments and differentiate rates after reviewing 2026 claims. That could compress the outpatient opportunity before SynPath scales, while biologic incumbents compete hard on price.

Catalysts and monitorables (next 12 months)

Expected timingCatalyst / monitorable
29 Oct 2026FY26 AGM: remuneration report vote, first AGM under Chair Hoare, possible trading commentary
Oct–Nov 2026Q1 FY27 trading update (if continued): constant-currency growth versus the about 21% FY26 run-rate; MTX trajectory
Before 31 Dec 2026BTM PMA submission to the FDA
Nov 2026CMS CY2027 PFS/OPPS final rules: any bundling or differentiated skin-substitute payments
1H FY27Remaining insurance recoveries; R&D Innovation Centre rebuilt and back in use
FY27SynPath US launch and early outpatient uptake; CMS coding decisions for BTM and MTX
FY27Regulatory validation of and transition to the new manufacturing facility; gross-margin recovery
FY27UK and EU MDR clearance for MTX; Japan regulatory progress; Mexico and Brazil registrations
Feb 20271H FY27 results: operating leverage, FCF, first disclosures under the new LTI framework
FY27Any business-development or licensing transaction for non-core NovoSorb® programs
OngoingSubstantial-holder register changes (FIL, State Street, Vanguard) and director dealings

Analyst verdict

PolyNovo enters FY27 as a better-governed, cash-generative and more professionally run company than it was 18 months ago, yet its share price is well below where it was then. The 2025 governance crisis has been addressed: there is a new Chair, three new directors, separate committees and an executive team heavily recruited from CSL. FY26 showed that the business model works at scale. Sales reached A$138.4m, underlying EBITDA rose 50% to A$13.4m, free cash flow was positive and the balance sheet is essentially debt-free. The technology still stands apart. A fully synthetic dermal matrix with infection resilience, a large and mostly independent evidence base, and a cost structure that suits CMS's move away from paying premiums for biologics is unusual in wound care.

The market is nonetheless right to discount the story. Reported growth has slowed sharply, and FY26 second-half sales barely grew on the first half. The FY26 gross-margin dip and the 1H profit collapse showed how much a single-site manufacturer depends on operations. The PMA, the main de-risking event, has already slipped once. At about 48x underlying EBITDA and about 4.7x EV/sales, the valuation still implies growth returning to above 20% with margin expansion, so the business needs to execute on several fronts at once.

Our synthesis is that PolyNovo has become an execution story with one binary catalyst (PMA filing, then approval) and one structural question (whether outpatient reimbursement turns SynPath into a second growth engine rather than a cost centre). The PMA submission before December 2026 and constant-currency growth staying at or above about 20% are the two tests that matter most. If both are met, the current price leaves meaningful upside. If either is missed, the shares are likely to keep trading on a "show-me" basis. On balance the risk/reward looks positive but conditional.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleJoined / tenurePrior rolesEducation

Bruce Peatey

Chief Executive Officer

Dec 2025

Led the US, Canada and Latin America businesses at Dentsply Sirona (about US$1.3bn operation); earlier Asia Pacific region lead; Abbott, Baxter, Biosensors International

BAppSc, MBA

Jan Gielen

Chief Financial Officer

Dec 2018

CFO of CardioScan (6 years); Finance Director of ICIX (Silicon Valley); Pitcher Partners

BBus (Acc), CA

Ed Graubart

President, North America

2019; President since Mar 2024

EBI (Biomet), DePuy Spine (J&J), NuVasive, Ceterix Orthopedics, Titan Spine

BSc

Dr Marthe D'Ombrain

Chief Scientific Officer

Jun 2026

CSL Executive Director & Head, Global Research Innovation; NED of AusBiotech

PhD (WEHI / University of Melbourne), GAICD

Allison Myers

Chief Quality and Regulatory Affairs Officer

Joined Oct 2025 as VP Quality; promoted Feb 2026

28 years at GSK (Australia and UK), including Site Director, GSK Melbourne

BSc (Pharmacology), BSc (Hons)

Amy Demediuk

General Counsel and Company Secretary

Feb 2026

CSL General Counsel (Global R&D and Strategy), 16+ years at CSL; Arnold Bloch Leibler

LLB (Hons), MIPL, GradDipACG

Kimberley Axon

Chief People Officer

Mar 2025

CPO at Dubber; I-MED Radiology; Sage; Weatherford

BPsych (Hons)

Tyson Parker

Chief Manufacturing and Supply Chain Officer

Sep 2026

Senior manufacturing leadership at CSL Seqirus

BSc (Biological Science), MBA

Board of Directors

DirectorRoleAppointedCommitteesBackground

Leon Hoare

Non-Executive Chair

Director 27 Jan 2016; Chair from 27/28 Oct 2025

Chair, Nominations

Former MD of Lohmann & Rauscher ANZ (to Dec 2025); 24 years at Smith & Nephew, including President Asia-Pacific Advanced Wound Management; NED of Medical Developments International (ASX: MVP)

Robert Douglas

Independent NED

14 Oct 2025

Audit & Risk

ResMed President and COO 2013–2023; Globus Medical (NYSE: GMED) board and audit committee

Dr Robyn Elliott

NED

28 Oct 2019 (Acting CEO 11 Mar 2025 to 1 Dec 2025)

Remuneration; Audit & Risk

Global Head, Strategic Portfolio Management at CSL Behring; former MD of IDT Australia

Christine Emmanuel-Donnelly

Independent NED

13 May 2020

Chair, Remuneration; Nominations

IP and business development executive; former CSIRO Executive Manager BD; Chair of Impedimed (ASX: IPD); MVP board

Dr Charmaine Gittleson

Independent NED

1 Apr 2026

Remuneration; Nominations

Former CSL Chief Medical Officer; Chair of Percheron Therapeutics; NED of Imugene and George Medicines

Andrew Lumsden

Independent NED

4 Jun 2021

Chair, Audit & Risk; Nominations

Former CEO, CFO and COO of Wellcom Worldwide Australasia; ex-PwC

David Williams (former)

Former Chair

Director 28 Feb 2014; resigned 27 Oct 2025

—

Held 21,655,000 shares at cessation

Board & Management Changes

DateChangeContext

Mar 2025

Kimberley Axon appointed CPO

People and culture build-out

7–11 Mar 2025

CEO Swami Raote asked to leave, then steps down immediately; Robyn Elliott Acting CEO

Followed media reports of an independent investigation into alleged bullying of senior executives (including Raote and CFO Gielen) by Chair Williams. Shares fell about 13% on 7 Mar 2025 and were about 40% below 24 Feb 2025 levels by mid-March (Stockhead).

Mar 2025

Spencer Stuart engaged to review board structure, skills and composition

Governance remediation

Oct 2025

Kingston Reid engaged for board training on workplace behaviour; former Westpac chair Lindsay Maxsted engaged to advise on governance matters

Disclosed the day before the Chair resigned (Capital Brief)

14 Oct 2025

Rob Douglas joins board

Board renewal

Oct 2025

Bruce Peatey named CEO (starts 1 Dec 2025)

Ends an eight-month interim period

27 Oct 2025

David Williams resigns as Chair after 11 years; Leon Hoare becomes Chair

Shareholder push-back ahead of the 28 Oct 2025 AGM; re-election resolution withdrawn

Feb 2026

Amy Demediuk (GC & CoSec) joins; Allison Myers promoted

Compliance and quality strengthening ahead of the PMA

1 Apr 2026

Charmaine Gittleson joins board

Clinical and regulatory board skills

1 Jun 2026

Marthe D'Ombrain becomes CSO

R&D reprioritisation

Sep 2026

Tyson Parker joins as CMSCO

Manufacturing scale-up and inspection readiness

Major Shareholders

HolderShares% voting powerAs atSource

FIL Limited (Fidelity International)

59,701,7828.64

Jun 2026

Substantial holder notice (FilingReader)

State Street Corporation

41,858,2536.06

26 Aug 2025 (may have changed)

Substantial holder notice (FilingReader)

The Vanguard Group

34,514,1425.00

18 Jun 2024 (may have changed)

Substantial holder notice (TipRanks)

David Williams (former Chair)

21,655,000

about 3.1 (computed)

27 Oct 2025 (holding at cessation)

AR2026

UBS Group AG

below 5%

—

Ceased 18 May 2026

FilingReader

Unnamed new substantial holder

—

≥5

25 Jun 2026 notice

InvestSMART announcements list

Competitive Landscape

Key Competitors

CompetitorCompeting productsSegment overlapPositioning vs PolyNovo

Integra LifeSciences (NASDAQ: IART)

Integra Dermal Regeneration Template ("Integra Skin"), PriMatrix, MediHoney

Dermal templates for burns and reconstruction (the closest substitute)

Incumbent bovine collagen-GAG template with long PMA history; has suffered quality remediation and supply constraints in 2024–2025

AVITA Medical (NASDAQ: RCEL / ASX: AVH)

RECELL (autologous cell harvesting), Cohealyx, PermeaDerm

Burns and trauma centres

Often used alongside dermal matrices rather than instead of them; also a competitor for burn-centre budgets

Organogenesis (NASDAQ: ORGO)

Apligraf, Dermagraft, PuraPly, Affinity, NuShield

Advanced wound care, mainly outpatient chronic wounds

Large outpatient incumbent; heavily exposed to the 2026 CMS reset

MiMedx Group

Placental and amniotic allografts (EPIFIX etc.)

Outpatient chronic wounds, surgical

Biologic allografts reimbursed in the 361 HCT/P class

Smith+Nephew

Grafix, PICO negative-pressure therapy, wound biologics

Advanced wound management

Diversified wound-care major; Chair Hoare is a former S&N executive

Kerecis (Coloplast)

Intact fish-skin grafts

Burns, trauma, chronic wounds

Biologic xenograft; well capitalised under Coloplast

Vericel

Epicel, NexoBrid (enzymatic debridement)

Large burns

Complementary or competitive in burn-centre workflows

MedSkin Solutions Dr. Suwelack

MatriDerm (collagen-elastin matrix)

Dermal templates, mainly Europe

Biologic template competitor in EMEA

PolyMedics Innovations

SUPRATHEL

Burns (partial thickness)

Both a competitor and a distribution partner in the UK/ANZ

Cadaveric allograft suppliers (for example MTF Biologics, tissue banks)

Temporary allograft skin cover

Large burns

The main incumbent practice that a BTM PMA aims to displace

Mölnlycke, Convatec, 3M/Solventum

Dressings and negative-pressure therapy

Wound management adjacent

Adjacent; compete for wound-care budgets

Peer Comparison FY2025

CompanyLatest FYRevenueYoY growth (%)Margin metricR&D intensity

PolyNovo

FY26 (Jun-26)

A$150.0m total; A$138.4m sales

16.1 (21.3 cc on sales)

Gross margin 89.0%; EBITDA margin 8.1% on total revenue; NPAT A$7.3m

3.5% (income-statement R&D only)

Integra LifeSciences

FY25 (Dec-25)

US$1,635.2m

1.5 (organic −0.7)

Adjusted EBITDA margin 19.4%

—

Organogenesis

FY25 (Dec-25)

US$563.0m net product revenue

17

Gross margin 76%; guides FY26 revenue down 25–38%

—

AVITA Medical

FY25 (Dec-25)

US$71.6m

11

Gross margin 82.1%; net loss US$48.6m

—

Company Snapshot

301

Employees

2004

Founded

Victoria, Australia

Headquarters

SWOT Analysis

Strengths

  • Exceptional gross margins. Company-defined gross margin was 95.6% in FY25 and 89.0% in FY26, against 76% at Organogenesis and 82.1% at AVITA in FY25.
  • Sustained growth. Commercial sales grew at a 38.5% CAGR from FY22 to FY26 (A$37.6m to A$138.4m).
  • Self-funding. FY26 operating cash flow was A$23.1m and free cash flow A$9.4m; cash was A$35.4m against A$3.6m of borrowings.
  • Independent clinical evidence. 535 articles and abstracts, nine textbook chapters, seven systematic reviews or meta-analyses, and about 94% independent authorship (AR2026).
  • Diversification beyond burns. US non-burn sales grew at a 52.8% three-year CAGR against 19.1% for large burns (FY26 presentation).
  • Second product scaling. MTX sales rose from A$6.7m to A$12.6m (+89.6%) in FY26 and are commercial in six markets.
  • Broad, growing customer base. The US had 880+ hospital accounts at FY26, and 252 new hospital accounts were added globally.

Weaknesses

  • Product concentration. BTM was A$125.8m of A$138.4m sales (90.9%) in FY26.
  • Geographic concentration. The US was 73.8% of FY26 sales, giving high exposure to US reimbursement and the USD/AUD rate.
  • Single manufacturing site. 1H FY26 NPAT was only A$3k after temporary manufacturing output reductions.
  • No on-label US burns indication. The PMA is still to be filed, and its timing slipped from "FY26" (Feb-2026 presentation) to "before end-CY2026" (Jul-2026).
  • Decelerating growth. Reported sales growth fell from 54.4% (FY24) to 28.9% (FY25) to 16.7% (FY26).
  • Thin statutory profitability. FY26 NPAT of A$7.3m is a 4.9% net margin; EBITDA of A$12.1m is an 8.1% margin.
  • Under-built incentives. No executive LTI existed in FY26; the plan only starts in FY27 (AR2026 Remuneration Report).

Opportunities

  • US PMA approval for full-thickness burns. It would allow on-label promotion, could support conversion of allograft users, and would place BTM in the CMS OPPS PMA class (APC 6000).
  • SynPath US outpatient launch in FY27. It uses existing HCPCS code A2006 under the CMS flat-rate model, and the US Part B skin-substitute market reached more than US$10bn in 2024.
  • MTX expansion into the UK and EU (MDR clearance targeted for FY27), Taiwan, Brazil and Mexico.
  • New markets. BTM registrations in 7 European countries and Brazil in FY26, with Japan entry under PMDA consultation.
  • Platform licensing through the FY27 business-development function, covering hernia, implantables and cell-therapy scaffolds (Beta Cell Technologies).
  • Competitor disruption. Integra's Tissue Technologies revenue fell 12.8% in Q4 FY25, and Organogenesis guides to a 25–38% FY26 revenue decline.
  • Operating leverage. Underlying EBITDA rose 50.4% on 16.7% sales growth while headcount stayed flat at about 301.

Threats

  • CMS policy volatility. CMS has signalled possible bundling of skin substitutes with application procedures and differentiated payments after reviewing 2026 claims.
  • PMA risk. FDA review could bring delays or requests for more data; the submission already slipped once after updated FDA QMS guidance in February 2026.
  • FX. The FY26 USD/AUD headwind cut US sales growth from 21.1% (cc) to 15.6% (reported).
  • Tariffs. US tariffs on Australian exports are flagged as a principal risk in AR2026.
  • Well-funded competitors. Integra has US$1.6bn of revenue, and Coloplast owns Kerecis.
  • Supply chain. AR2026 lists dependence on third-party raw-material suppliers as a key risk.
  • Governance and reputation. The 2025 bullying allegations against the former Chair and the CEO's removal hurt market confidence; shares were about 40% lower within weeks.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025Health Canada clears MTX 2 mmExpands MTX into Canada
May 2025TGA clears MTX 4 mm and 6 mmCompletes the Australian MTX range
7 May 2025Presentation at the Macquarie Australia ConferenceInvestor engagement during the leadership vacuum
21 May 2025New substantial holder noticeShareholder churn after governance turmoil
10 Jun 2025Swami Raote's employment formally endsCloses the CEO transition
Jun 2025FDA 510(k) clearance for BTM up to 6 mm thicknessBroadens BTM for deeper defects
Jun 2025Record month: commercial sales A$12.8m, total revenue A$13.7mExit-rate evidence
Jul 2025CMS proposed CY2026 rule: a uniform flat payment for skin substitutes (reported at about US$806 per sq inch)PNV shares jumped. The interim CEO said NovoSorb® should stay profitable and the outpatient market could open up.
29 Jul 2025FY25 trading update: sales A$118.6m (+28.9%), cash A$33.5m (from A$22.0m in March), supply into 46 countriesShares rose about 11%
7–29 Aug 2025UBS becomes, then ceases to be, a substantial holder; State Street raises its stake to 6.06% (26 Aug)Institutional repositioning
25 Aug 2025FY25 audited results: NPAT A$13.2m (+151%), EBITDA A$11.2mProfit roughly double consensus, per Capital Brief
Oct 2025Q1 FY26 trading update: sales A$34.7m (+33.3%), US +33.4%, ROW +33.1%, MTX A$2.9m (+175%), EBITDA positive, cash A$23.2m at 30 SepStrong start; broker upgrades (Evans & Partners Speculative Buy, A$2.65 target; Macquarie Outperform, A$2.00)
Oct 2025Bruce Peatey appointed CEO, effective 1 Dec 2025Permanent, Australia-based CEO
14 Oct 2025Rob Douglas (ex-ResMed COO) joins boardBoard renewal
Oct 2025Allison Myers joins as VP QualityQuality build-out ahead of the PMA
26 Oct 2025Board discloses governance remediation (Kingston Reid training; Lindsay Maxsted advisory)Response to the allegations about the Chair
27 Oct 2025Chair David Williams resigns; Leon Hoare appointed ChairGovernance overhang removed; shares rose about 4.8%
28 Oct 2025FY25 AGMWilliams re-election resolution withdrawn
31 Oct 2025CMS CY2026 Physician Fee Schedule final rule: most skin substitutes become incident-to supplies at about US$127.28/cm² from 1 Jan 2026. PolyNovo submits its clinical evidence package to CMS.Changes the US outpatient economics; opportunity for lower-cost synthetics
4 Nov 2025Fire at the standalone R&D Innovation CentreOperational disruption; no injuries
21 Nov 2025CMS OPPS final rule: separate APCs for PMA (6000), 510(k) (6001) and 361 HCT/P (6002) skin substitutesA future PMA could place BTM in a distinct payment class
1 Dec 2025Bruce Peatey starts as CEORobyn Elliott returns to the board on 12 Dec 2025
1 Jan 2026New CMS skin-substitute payment framework takes effectUS outpatient reset; disruption for biologic competitors
19 Jan 20261H FY26 trading update: sales A$68.2m (+26%), MTX A$6.2m (+195%); CMS coding requestsConfirms momentum; PMA said to be on track for FY26
Feb 2026Amy Demediuk appointed GC & CoSec; Allison Myers promoted to CQRAOCompliance capability
12 Feb 2026Insurers grant written indemnity for the R&D fire; rebuild by Sep 2026Financial impact neutralised
20 Feb 20261H FY26 results: adjusted EBITDA A$4.7m (+82%), NPAT A$3k, gross margin 88.8%, 95 new hospital customers; investor hub launchedWeak statutory profit because of manufacturing output reductions and FX
24 Feb – 12 Mar 2026On-market share purchases by directors Lumsden, Hoare and Douglas at about A$0.91–0.94Insider buying near multi-year lows
1 Apr 2026Dr Charmaine Gittleson joins boardClinical and regulatory board expertise
22 Apr 2026Dr Marthe D'Ombrain named CSO (effective 1 Jun 2026)R&D reset
28 Apr 2026Remuneration and Nominations Committees separatedGovernance maturity
14 May 2026Investor presentation on 1H FY26 performanceInvestor engagement
18–20 May 2026UBS ceases to be a substantial holderHolder churn
Jun 2026FIL cuts its stake from 9.65% to 8.64%; an unnamed holder becomes substantial (25 Jun)Register rotation
23 Jul 2026FY26 trading update: total revenue A$150.0m, sales A$138.4m, OCF A$24.0m (unaudited); PMA timing revised to before end-CY2026Positive free cash flow; PMA timing pushed back from "FY26"
26 Aug 2026FY26 audited results: NPAT A$7.3m, EBITDA A$12.1m, underlying EBITDA A$13.4m (+50%), FCF A$9.4m; record July salesMargin inflection; FY27 priorities set
Sep 2026Tyson Parker appointed Chief Manufacturing and Supply Chain OfficerManufacturing transition leadership
15 Sep 2026FY26 Annual Report lodged with the ASXNew remuneration framework (LTI from FY27)
24 Sep 2026Shares close at about A$0.98; average analyst target about A$1.28 (cut from A$1.75 in June 2026)Shares near cyclical lows
29 Oct 2026 (scheduled)FY26 Annual General MeetingFirst AGM under the new Chair

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

7 charts
Income Statement: Revenue & Gross Profit: Total revenue incl. BARDA and other income rose from AUD 41.9 Mn in FY2022 to AUD 150 Mn in FY2026.
Polynovo Ltd. — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Total revenue incl. BARDA and other income41.966.5104.8129.2150
NovoSorb commercial sales37.659.692118.6138.4
BARDA revenue———8.65.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.